Skip to main content
    E

    Emergent Biosolutions Inc (EBS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $5.61
    -0.20 (-3.44%)

    Market Cap: $298.72M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Emergent Biosolutions Inc (EBS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Emergent Biosolutions (EBS) has a market cap of $298.72M and an enterprise value of $630.72M. It kept -40.16% of revenue as net income over the last 12 months. Its net debt of $332.00M equals 111.14% of its market cap.

    Total Valuation

    Enterprise value is 111.14% above the market cap, as debt exceeds cash.

    Market Cap$298.72M
    Enterprise Value$630.72M
    Latest price (Nov 17, 2026)$5.61

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 2, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.58% in the quarter ended Sep 30, 2026 and shrank 1.71% a year over 2 years.

    Shares Outstanding51.30M
    Shares Change (YoY)-3.57%
    Shares Change (QoQ)-0.58%
    Share Count Growth (2Y CAGR)-1.71%

    Valuation Ratios

    Sales and book value multiples are 0.4x and 0.9x. Its year-end P/S ranged from 0.1x to 3.8x from 2016 to 2025.

    Forward P/E19.2x
    P/S Ratio0.4x
    Forward P/S0.5x
    P/B Ratio0.9x
    P/TBV Ratio4.7x
    P/FCF Ratio1.5x
    P/OCF Ratio1.5x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 3.3x free cash flow.

    EV / Sales1.0x
    EV / FCF3.3x

    Price Statistics

    The stock is down 44.51% over 52 weeks and trades 13.56% below its 50-day average.

    Beta (1Y)1.11
    52-Week Change-44.51%
    1-Month Change-11.79%
    3-Month Change+14.72%
    6-Month Change-30.40%
    5-Year Change-85.71%
    10-Year Change-74.51%
    Total Return (1Y)-44.51%
    Total Return (3Y CAGR)+39.86%
    Total Return (5Y CAGR)-32.31%
    Return vs SPY (1Y)-56.12%
    Max Drawdown (1Y)-67.99%
    Max Drawdown (3Y)-71.16%
    Sharpe Ratio (1Y)-0.81
    Correlation with SPY (1Y)0.21
    50-Day Average$6.49
    200-Day Average$7.68
    52-Week Range$4.36 to $14.06
    RSI (14 Days)35.5
    Average Volume (20 Days)1.05M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.58x current liabilities, and total debt is 1.62x shareholder equity.

    Current Ratio4.58x
    Quick Ratio2.27x
    Debt / Equity1.62x
    Debt / FCF2.69x
    Interest Coverage2.16x

    Returns and Efficiency

    Return on invested capital is -20.54% over the last 12 months, against a 5-year average of -7.77%.

    Return on Equity (ROE)-83.24%
    Return on Assets (ROA)-26.20%
    Return on Invested Capital (ROIC)-20.54%
    Return on Capital Employed (ROCE)-19.31%
    ROE (5Y Average)-29.63%
    ROA (5Y Average)-10.14%
    ROIC (5Y Average)-7.77%
    Asset Turnover0.53x
    Inventory Turnover1.15x
    Receivables Turnover4.85x
    Cash Conversion Cycle338 days

    Scores

    EBS has an Altman Z-Score of 0.36, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score0.36
    Altman Z ZoneDistress
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $649.10M over the last 12 months is down 17.72% from the 12 months before.

    Revenue$649.10M
    Revenue Growth (YoY)-17.72%
    Gross Profit$314.30M
    Operating Income-$179.80M
    Pretax Income-$240.00M
    Net Income-$260.70M
    EBITDA-$73.00M
    EBIT-$168.60M
    Reported EPS (TTM)-$0.04

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 31.47% of the $995.20M in total assets.

    Cash and Equivalents$175.70M
    Total Debt$507.70M
    Net Debt$332.00M
    Net Debt Per Share$6.47
    Working Capital$436.20M
    Shareholder Equity$313.20M
    Book Value Per Share$6.11
    Tangible Book Value$60.70M
    Tangible Book Per Share$1.18
    Total Assets$995.20M
    Total Liabilities$682.00M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $11.70M of capital spending, operating cash flow left $188.40M of free cash flow.

    Operating Cash Flow$200.10M
    Capital Expenditures$11.70M
    Free Cash Flow$188.40M
    FCF Per Share$3.67
    Depreciation and Amortization$95.60M
    Share Repurchases$27.20M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -27.70%.

    Gross Margin48.42%
    Operating Margin-27.70%
    Pretax Margin-36.97%
    Net Margin-40.16%
    EBITDA Margin-11.25%
    EBIT Margin-25.97%
    FCF Margin29.02%
    Gross Margin (5Y Average)58.17%

    Growth

    Revenue grew 433.23% a year over 3 years.

    Revenue Growth (3Y CAGR)+433.23%
    Revenue Growth (5Y CAGR)-13.98%
    EPS Growth (5Y CAGR)-28.18%
    FCF Growth (5Y CAGR)-16.87%
    Book Value Per Share Growth (2Y CAGR)-10.71%
    Tangible Book Per Share Growth (2Y CAGR)+1.55%

    Revenue and profit by year

    Dividends and Yields

    EBS does not pay a dividend. Its free cash flow yield is 65.46%.

    FCF Yield65.46%
    Buyback Yield9.28%
    Shareholder Yield9.28%

    Peer Position

    Against 9 similar companies, EBS has the 8th highest P/S.

    P/S Ratio0.4x vs 1.4x median
    ROIC-20.54% vs -17.82% median
    Revenue Growth (Trailing 4 Quarters, YoY)-17.72% vs +10.75% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -2.70% and EPS growth at -16.48% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-2.70%
    EPS Growth Forecast (2Y CAGR)-16.48%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EBS

    What is EBS's market cap?

    Emergent Biosolutions has a market cap of $298.72M. Its enterprise value, which adds debt and subtracts cash, is $630.72M.

    How many shares of EBS are outstanding?

    Emergent Biosolutions has 51.30M shares outstanding. The count is down 3.57% from a year earlier.

    Does EBS pay a dividend?

    No. Emergent Biosolutions does not pay a dividend.

    How much debt does EBS have?

    Emergent Biosolutions has $507.70M of total debt and $175.70M of cash and equivalents, a net debt position of $332.00M.